Leeds Prospective Remission Clinic

Evidence suggests that despite achieving remission, a proportion of patients may still progress, therefore our primary research aim is to characterise remission using imaging (ultrasound) and immunological blood tests (T-cell subsets) as well as involve patients via Patients Reported Outcome (PRO). Our secondary research aim is to identify predictors of flare versus sustained remission, comparing two separate groups: those who continue treatment and those who wish to reduce therapy. The ultimate aim is to be able to inform/direct the tapering decisions based on individual patient characteristics to ensure those who are able to can reduce treatment and those at high risk of losing remission by tapering are advised against it.

Publication list:

Hanna L Gul 1, Joana F Ferreira, Paul Emery Remission in rheumatoid arthritis: is it all the same? Expert Rev Clin Pharmacol. 2015;8(5):575-86.  doi: 10.1586/17512433.2015.1061429

Hanna L Gul, Leticia Garcia-Montoya, Laurence M Duquenne, Peta E Pentony, Luiz E Oliviera and Paul Emery. Predicting successful tapering of biologic therapy for patients with rheumatoid arthritis in remission – Why are we still using clinical remission criteria to inform decisions? Rev Press. 2017; 1(1): 6-18.  doi.org/10.28964/RevPress-1-102

HL Gul , G Eugenio , T Rabin , A Burska , R Parmar , J Wu , F Ponchel , P Emery. Defining remission in rheumatoid arthritis: does it matter to the patient? A comparison of multi-dimensional remission criteria and patient reported outcomes. Rheumatology, 2020 Mar 1;59(3):613-621.  doi: 10.1093/rheumatology/kez330.

F Ponchel, AN Burska, L Hunt, H Gul, T Rabin, R Parmar, MH Buch, PG Conaghan, P Emery. T-cell subset abnormalities predict progression along the Inflammatory Arthritis disease continuum: implications for management. Nature Scien Reports. 2020. DOI: 10.1038/s41598-020-60314-w